{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:17Z","timestamp":1790286917483,"version":"4.1.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Cutaneous toxicities associated with BRAF inhibitor treatment in patients with metastatic melanoma have been well described. We present a rare association of granulomatous dermatitis in association with the BRAF inhibitor vemurafenib. Three patients with metastatic melanoma all presented with asymptomatic papular eruptions 8\u201321 months into vemurafenib therapy. Skin biopsies confirmed the diagnosis of granulomatous dermatitis. Other causes of granulomatous dermatitis including infectious agents and sarcoid were excluded. Treatment with potent topical and oral steroids improved the eruptions, but only after the cessation of vemurafenib did all 3 cases of granulomatous dermatitis completely resolve within 2 weeks. It is important to recognize that this association, unlike most other BRAF inhibitor\u2013related skin toxicities, can occur many months after commencement of therapy and that vemurafenib treatment can be continued without clinically significant adverse effects.<\/jats:p>","DOI":"10.1097\/dad.0000000000001276","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T01:43:16Z","timestamp":1547430196000},"page":"214-217","source":"Crossref","is-referenced-by-count":12,"title":["BRAF Inhibitor\u2013Associated Granulomatous Dermatitis: A Report of 3 Cases"],"prefix":"10.1097","volume":"41","author":[{"given":"Eugene Liat","family":"Hui Ong","sequence":"first","affiliation":[{"name":"Dermatology Department, Chelsea Westminster Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishika","family":"Sinha","sequence":"additional","affiliation":[{"name":"Dermatology Department, West Middlesex University Hospital, Middlesex, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilan","family":"Jmor","sequence":"additional","affiliation":[{"name":"Oncology Department, University College Hospital London, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Fearfield","sequence":"additional","affiliation":[{"name":"Dermatology Department, Chelsea and Westminster, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med."},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1203475416670368","article-title":"Prospective case series of cutaneous adverse effects associated with dabrafenib and trametinib","volume":"21","author":"Lacroix","year":"2017","journal-title":"J Cutan Med Surg."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/jdv.12449","article-title":"Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients","volume":"29","author":"Vanneste","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"5361569","DOI":"10.1155\/2016\/5361569","article-title":"Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature","volume":"2016","author":"Gencler","year":"2016","journal-title":"Dermatol Res Pract."},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaad.2017.04.761","article-title":"Persistent granulomatous cutaneous drug eruption to a BRAF inhibitor","volume":"76","author":"Wali","year":"2017","journal-title":"JAAD."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/DAD.0000000000000281","article-title":"BRAF inhibitor\u2013induced antitumoral granulomatous dermatitis eruption in advanced melanoma","volume":"37","author":"Garrido","year":"2015","journal-title":"Am J Dermatopathol."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/CMR.0000000000000186","article-title":"Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib","volume":"25","author":"Jansen","year":"2015","journal-title":"Melanoma Res."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jamadermatol.2013.7919","article-title":"Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma","volume":"150","author":"Park","year":"2014","journal-title":"JAMA Dermatol."},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjd.12279","article-title":"Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases","volume":"169","author":"Green","year":"2013","journal-title":"Br J Dermatol."},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archderm.142.2.198","article-title":"Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors","volume":"142","author":"Deng","year":"2006","journal-title":"Arch Dermatol."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00000372-200108000-00003","article-title":"Interstitial granulomatous drug reaction with a histological pattern of interstitial granulomatous dermatitis","volume":"23","author":"Perrin","year":"2001","journal-title":"Am J Dermatopathol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201903000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:01:47Z","timestamp":1694149307000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201903000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000001276","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}